Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer.

ABSTRACT:

Background

Prognostication tools for early-stage non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT) are currently lacking. The purpose of this study was to develop and externally validate a nomogram to predict overall survival in individual patients with peripheral early-stage disease.

Methods

A total of 587 NSCLC patients treated with biologically effective dose > 100 Gy₁₀ were eligible. A Cox proportional hazards model was used to build a nomogram to predict 6-month, 1-year, 3-year and 5-year overall survival. Internal validation was performed using bootstrap sampling. External validation was performed in a separate cohort of 124 NSCLC patients with central tumors treated with SBRT. Discriminatory ability was measured

SUBMITTER: Baker S 

PROVIDER: S-EPMC7178957 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature